Actos Record-breaking Personal Injury Verdict Tied To Drug Revenue
This article was originally published in The Pink Sheet Daily
Executive Summary
Jury awarded $1.5 million in compensatory damages and $9 billion in punitive damages against Takeda and Lilly; judge said jurors could consider Takeda’s destruction of evidence, which included a concern about Actos’ “margin of safety.”
You may also be interested in...
Takeda Shareholders Approve Weber As COO Setting Up Leadership Handover
Christophe Weber wins shareholder approval as chief operating officer at Takeda as expected, setting up a leadership change at Japan’s top, and oldest, drug company over the opposition of some family members.
Rearguard Battle At Takeda Unlikely To Derail Globalization Plans
The planned appointment of Christophe Weber as chief operating officer at Asia’s leading pharmaceutical company has ruffled feathers among traditionalists fearful of change.
Charting The Course Of Product Liability: From Yasmin/Yaz To Actos
Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.